FDA Approves ZEJULA — GlaxoSmithKline LLC

# FDA Approves GlaxoSmithKline's ZEJULA (Niraparib Tosylate) for Oral Administration GlaxoSmithKline LLC has received FDA approval for ZEJULA (niraparib tosylate), an oral PARP inhibitor that expands the company's oncology portfolio and strengthens its competitive position in the poly-ADP-ribose polymerase inhibitor market, which continues to grow with increasing adoption in multiple cancer indications. The oral formulation approval could enhance patient convenience and potentially drive market share gains for GSK in a